Detailed Explanation
Synthetic heptapeptide analog of ACTH(4–10) (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics in Moscow. Semax retains the neurotrophic and neuroprotective properties of the ACTH fragment without adrenal-stimulating (steroidogenic) activity.
It is approved in Russia as a nasal spray for conditions including stroke recovery, cognitive disorders, and optic nerve disease. Research suggests mechanisms involving BDNF/NGF upregulation, modulation of serotonergic and dopaminergic systems, and immune system effects. Like selank, semax is not FDA-approved and is used as a research peptide outside of Russia.
Key Facts
- Synthetic heptapeptide analog of ACTH(4–10) (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics in Moscow.
- Semax retains the neurotrophic and neuroprotective properties of the ACTH fragment without adrenal-stimulating (steroidogenic) activity.
- It is approved in Russia as a nasal spray for conditions including stroke recovery, cognitive disorders, and optic nerve disease.
- Research suggests mechanisms involving BDNF/NGF upregulation, modulation of serotonergic and dopaminergic systems, and immune system effects.
- Like selank, semax is not FDA-approved and is used as a research peptide outside of Russia.
Part of the PeptideBond.com education network
Educational Disclaimer
PeptideDefinition.com provides educational content about peptide science. Not medical advice. Consult a licensed healthcare provider for medical decisions.